Highlights

  • EBR Systems has confirmed a multi-city investor roadshow across Australia in October 2026.
  • Company Leadership and an external cardiac specialist will present on recent developments.
  • Sessions will be held in three major Australian cities over a three-day window.
  • Attendance is free of charge but requires registration ahead of a set deadline.

EBR Systems, Inc. (ASX:EBR), the developer of what it describes as the world's only wireless cardiac pacing device for heart failure, has announced that it will host an investor roadshow across Australia in late October 2026. The announcement, made on 9 September 2026, sets out a schedule of in-person events designed to update the Investment community on the company's recent milestones and its approach to bringing its technology to a wider market. The roadshow will bring together company leadership and outside clinical expertise in a single forum, giving attendees an opportunity to hear directly about the company's flagship product, the WiSE System, and the broader commercialisation path the company is pursuing.

Roadshow Details and Schedule

According to the announcement, the investor roadshow will run from 27 to 29 October 2026, with dedicated events planned in Brisbane, Melbourne and Sydney. This three-city format allows the company to reach investors across different states within a single week, consolidating its outreach into a compact and clearly defined window. Attendance at each session is free of charge, though prospective attendees are required to register in advance through a SurveyMonkey link, with the registration deadline set for 21 October 2026. The structured registration process suggests the company is seeking to manage attendance numbers and plan each session appropriately, while still keeping the events accessible to a broad base of interested parties. The timing, in the final week of October, positions the roadshow ahead of the calendar year-end, giving the company a further opportunity to communicate progress before the close of 2026. Holding separate sessions in each city, rather than a single centralised event, also allows the company to engage more directly with local investor networks in each location, rather than relying solely on a single national gathering or a virtual-only format. For a company operating in the medical device sector, where technical detail and regulatory context often matter as much as commercial updates, an in-person format of this kind can allow for more detailed discussion than a shorter written release would typically permit.

Leadership and Clinical Presenters

Presentations across the three cities will be led by Andrew Shute, Chief Corporate Development Officer at EBR Systems, who is expected to cover the company's recent milestones alongside its broader commercialisation strategy. His sessions are intended to give attendees a company-level view of how EBR Systems intends to grow the reach of its technology going forward. Joining Mr Shute will be Dr Robert Canby of the Texas Cardiac Arrhythmia Institute, who will speak specifically to the clinical applications of the WiSE System. The inclusion of an independent clinical voice alongside company management is notable, as it gives the roadshow both a corporate and a medical perspective, allowing attendees to hear how the device is viewed and used from a clinical standpoint as well as from a commercial one. This pairing of a corporate development lead with a practising cardiac specialist reflects the technical nature of the underlying product, which sits at the intersection of engineering and cardiology.

Key Insights

The announcement of a three-city Australian investor roadshow gives EBR Systems a structured platform to communicate directly with the local investment community during a defined window in late October 2026. By pairing its own Chief Corporate Development Officer with an external cardiac specialist from the Texas Cardiac Arrhythmia Institute, the company is presenting both a commercial and a clinical narrative around its WiSE wireless cardiac pacing system. The free-to-attend, registration-based format across Brisbane, Melbourne and Sydney is designed to make the sessions accessible while allowing the company to manage turnout ahead of the 21 October registration deadline. For those following the company, the key facts remain straightforward: the roadshow is an informational and engagement exercise, and the WiSE System continues to be investigational in most markets globally, with current sales authorisation limited to the United States. Investors and other interested observers wanting a fuller picture of the company's plans may find the scheduled sessions a useful opportunity to hear directly from both company management and independent clinical expertise.